ATE511654T1 - Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern - Google Patents

Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern

Info

Publication number
ATE511654T1
ATE511654T1 AT03773780T AT03773780T ATE511654T1 AT E511654 T1 ATE511654 T1 AT E511654T1 AT 03773780 T AT03773780 T AT 03773780T AT 03773780 T AT03773780 T AT 03773780T AT E511654 T1 ATE511654 T1 AT E511654T1
Authority
AT
Austria
Prior art keywords
low
antibodies
mab
recruited
antigens
Prior art date
Application number
AT03773780T
Other languages
German (de)
English (en)
Inventor
Romeuf Christophe De
Christine Gaucher
Arnaud Glacet
Frederic Dhainaut
Dominique Bourel
Nicolas Bihoreau
Emmanuel Nony
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0211416A external-priority patent/FR2844521B1/fr
Priority claimed from FR0211415A external-priority patent/FR2844520B1/fr
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Application granted granted Critical
Publication of ATE511654T1 publication Critical patent/ATE511654T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03773780T 2002-09-13 2003-09-15 Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern ATE511654T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0211416A FR2844521B1 (fr) 2002-09-13 2002-09-13 Mesure de la production de cytokines comme marqueur d'activation de cellules effectrices
FR0211415A FR2844520B1 (fr) 2002-09-13 2002-09-13 Utilisation d'un anticorps induisant la secretion de cytokines en therapie
PCT/FR2003/002715 WO2004024768A2 (fr) 2002-09-13 2003-09-15 Anticorps induisant la production de cytokines

Publications (1)

Publication Number Publication Date
ATE511654T1 true ATE511654T1 (de) 2011-06-15

Family

ID=31995630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03773780T ATE511654T1 (de) 2002-09-13 2003-09-15 Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern

Country Status (9)

Country Link
US (2) US7595165B2 (fr)
EP (2) EP2092939A3 (fr)
JP (1) JP4368800B2 (fr)
AT (1) ATE511654T1 (fr)
AU (1) AU2003282161B2 (fr)
CA (1) CA2498315C (fr)
DK (1) DK1537419T3 (fr)
IL (1) IL167385A (fr)
WO (1) WO2004024768A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024768A2 (fr) * 2002-09-13 2004-03-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps induisant la production de cytokines
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2895086B1 (fr) * 2005-12-16 2012-10-05 Lab Francais Du Fractionnement Potentialisation de l'apoptose par des anticorps monoclonaux
DE602007013068D1 (de) * 2006-09-13 2011-04-21 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
FR2968561B1 (fr) 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
FR3064007A1 (fr) 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps pour le traitement de cancers
JP7649244B2 (ja) * 2019-02-14 2025-03-19 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 免疫細胞の効力をアッセイするための刺激剤の使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059540A1 (fr) * 1999-04-05 2000-10-12 Biocrystal Ltd. Trousses et procedes de titrage pour une activation par des complexes immuns contenant des antigenes shed
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2463879C (fr) * 2001-10-25 2012-12-04 Genentech, Inc. Compositions de glycoproteine
WO2004024768A2 (fr) * 2002-09-13 2004-03-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps induisant la production de cytokines

Also Published As

Publication number Publication date
EP2092939A3 (fr) 2011-12-21
US20050249732A1 (en) 2005-11-10
CA2498315A1 (fr) 2004-03-25
JP4368800B2 (ja) 2009-11-18
AU2003282161A1 (en) 2004-04-30
CA2498315C (fr) 2013-01-29
WO2004024768A3 (fr) 2004-09-30
EP2092939A2 (fr) 2009-08-26
DK1537419T3 (da) 2011-06-27
EP1537419B1 (fr) 2011-06-01
JP2006517087A (ja) 2006-07-20
US20100323368A1 (en) 2010-12-23
AU2003282161B2 (en) 2010-06-24
IL167385A (en) 2012-08-30
US7595165B2 (en) 2009-09-29
WO2004024768A2 (fr) 2004-03-25
EP1537419A2 (fr) 2005-06-08

Similar Documents

Publication Publication Date Title
US8603477B2 (en) Use of anti-CS1 antibodies for treatment of rare lymphomas
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
FR2858235B1 (fr) Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
HRP20191609T1 (hr) Protein
WO2004029092A8 (fr) Anticorps pour adcc et induisant la production de cytokines.
CR20130154A (es) Proteínas de la unión a il-12/p40 (divisional exp. 9599)
LTC2380910I2 (lt) Antigeną surišančios molekulės su padidintu Fc receptoriaus prisirišimo gimingumu ir efektorine funkcija
RU2006144820A (ru) Антитела, связывающиеся с рецепторами kir2dl1,-2,-3 и не связывающиеся с рецептором kir2ds4, и их терапевтическое применение
PL374587A1 (en) Pharmaceutical compositions directed to erb-b1 receptors
RU2008133032A (ru) Антитела к ох-2/сd200 и их применение
MY202133A (en) Anti-sortilin antibodies and methods of use thereof
UA92504C2 (en) Anti-myostatin monoclonal antibody
NZ616992A (en) Anti-ilt7 antibody
KR20170122258A (ko) Cd20 결합 분자 및 그의 용도
DK0812333T3 (da) Bispecifikt antistof, som er effektivt til behandling af B-cellelymfom og cellelinie
WO2003078600A3 (fr) Anticorps monoclonaux humains diriges contre la proteine m2 du virus de la grippe et methodes de production et d'utilisation de ceux-ci
RU2406730C2 (ru) Гуманизированное моноклональное анти-cd20-антитело
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NO973447D0 (no) Monoklonale antistoffer som er spesifikke for forskjellige epitoper i human-gp 39, og fremgangsmåter for deres anvendelse i diagnose og terapi
PE20030846A1 (es) Anticuerpos para cd40
ATE488530T1 (de) Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
WO2006133450A3 (fr) Therapie a anticorps diriges contre cd19 a des fins de transplantation
WO2004108766A3 (fr) Anticorps anti-hgf-r et leur utilisation
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1537419

Country of ref document: EP